BioCardia announced that the FDA agreed on two possible marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no safety or performance concerns raised. The FDA's preferred approval route is simultaneous with the CardiAMP cell therapy system for heart failure, but a follow-up pre-submission could allow Helix approval via the DeNovo pathway. This alignment supports BioCardia's goal to independently clear Helix to enhance development and partnerships for other cell, gene, and protein therapies. Upcoming milestones include FDA meetings and clinical presentations in May 2026.
AIX Alpha has introduced a new AI-powered automated trading platform designed to help retail traders manage the increasing volatility in digital asset markets, particularly XRP. The system analyzes over 100,000 market signals daily and adjusts strate...
SpaceX is preparing for the largest IPO in history with its Starlink satellite network, targeting a valuation between $1.75 trillion and $2 trillion. This IPO will surpass previous tech giants' offerings by a huge margin and highlights the rapid grow...
Caleres has been upgraded from a 'sell' to a 'hold' rating following stronger recent financial performance, driven by the Stuart Weitzman acquisition which boosted revenue. However, profitability is still under pressure, with an adjusted net loss par...
Oil tanker traffic through the Strait of Hormuz is unlikely to return to prewar levels even if the US and Iran reach a deal, due to ongoing geopolitical risks and Iran's control over the strait. Shipowners face risks from potential renewed conflict a...
In 2026, Berkshire Hathaway's shares have fallen nearly 11% while the S&P 500 surged over 35%, driven by tech stocks benefiting from AI optimism. Berkshire's conservative approach, with minimal AI exposure and nearly $400 billion cash reserves, contr...
